70 results about "Glypican" patented technology

The invention relates to a dual-targeting genetically modified immunologic effector cell aiming at GPC3 (glypican-3) and ASGPR1 (asialoglycoprotein receptor 1) and applications of the dual-targeting genetically modified immunologic effector cell. The invention discloses the gene-modified immunologic effector cell capable of simultaneously identifying GPC3 and ASGPR1 for the first time, and the gene-modified immunologic effector cell can be used for the treatment of the GPC3 and ASGPR1 double-positive tumor, such as liver cancer.

Compositions and methods of treatment for abnormal bone density are disclosed based upon the finding that sclerostin must be bound to glypican in order to inhibit bone deposition. Methods for identifying agents that inhibit the glypican-sclerostin interaction are disclosed for treatment of bone deposition disorders. Diagnostic methods are also disclosed.

Glycosylphosphatidylinositol-(GPI-) anchored HSPG glypican-1 is strongly expressed in human breast and pancreatic cancer—both by the cancer cells and in the case of pancreatic cancer the adjacent fibroblasts—whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors: fibroblast growth factor-2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). Treatment of MDA-MB-231 and MDA-MB-468 breast cancer cells with PI-PLC abrogates the mitogenic response to two heparin-binding growth factors, heparin-binding epidermal growth factor-like growth factor (HB-EGF) and fibroblast growth factor-2 (FGF-2). Syndecan-1 is also expressed at high levels in breast cancer tissues as well as breast cancer cells by comparison with breast normal tissues. Temporary or permanent transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. Glypican can be used to detect the carcinoma in vitro and therapeutics that either bind to (e.g., antibodies or drugs), remove (e.g., enzymes) or prevent the expression (e.g., antisense constructs) of surface of the extracellular domain of glypican-1 are effective in retarding the growth of glypican-responsive carcinomas.

The present invention relates to a nanobody of Glypican 3 with outstanding high stability and a preparation method thereof, and also relates to the amino acid sequence of the nanobody, a gene coding sequence and an expression vector capable of expressing the nanobody and host cell. The amino acid sequence of the nanobody to GPC3 provided by the present invention is shown in SEQ ID NO: 7, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO: 8. The GPC3 nanobody involved in the present invention can specifically recognize liver cancer cells with high GPC3 expression by binding to the GPC3 expressed on the cell membrane. The antibody has outstanding high stability, and can be used in the functional research of GPC3, and can also be used in the development of diagnostic reagents and therapeutic drugs for hepatocellular carcinoma.